A Phase 3 interventional study of 3-6mg QLM1016 and 10-20 mg Aripiprazole oral solution film in Schizophrenia, sponsored by Qilu Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 252 studies in Schizophrenia with a site in China — 64 open to participants now, 68 under way, 4 of them phase 3. Schizophrenia · China.
Among the 252 studies in Schizophrenia with a site in China, this one is the 29th largest by planned enrollment of the 216 interventional ones that give a count, is one of 16 that started in 2025, is one of 35 in phase 3, reaches primary completion later than 24 of the 67 other live ones, and was the 198th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →64 of the 252 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–35
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–60
Central South University · Sites in China
Ages 18–50
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–60
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
252 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 16 · Phase 3 38 · Phase 4 33
First in 2002; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 402 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 216 interventional studies, 300 across the 36 observational. Of the 120 that completed or were terminated, 21 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 252 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 2 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
19 of the studies in Schizophrenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT07521683NeuShen TherapeuticsA Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia | 2026-11 |
| NCT06802939Shanghai Mental Health CenterRTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography | 2026-12-10 |
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT07356765Tianjin Anding HospitalBerberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms | 2027-01 |
Add all 19 to your calendar (.ics) → With an account.
Among the 252 studies in Schizophrenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 3-6mg QLM1016
Drug: 10-20 mg Aripiprazole oral solution film
3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks
10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.
change from baseline to week 6 in the Positive and Negative Syndrome Scale (PANSS) total score
Time frame: Time Frame: 6 weeks
Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start May 2025 → Oct 2025 and primary completion Jul 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Pharmaceutical Co., Ltd. →